We generated alectinib‐induced DTP cells from a patient‐derived ALK+ non‐small‐cell lung cancer (NSCLC) cell line and screened 3114 agents in the anticancer compounds library (TargetMol). Here, ALK is linked to non-small cell lung carcinoma.